ELV Stock Analysis — Elevance Health
Sector: Healthcare
AI Verdict
ELV is cheap for the growth you're getting, and its entrenched position in health insurance makes the current earnings trajectory more credible than most.
Competitive Moat
Elevance Health operates as a national health insurer with scale-driven bargaining power over providers and exclusive Blue Cross/Blue Shield branding in key states. Its defensibility comes from entrenched relationships with employers and government plans, plus regulatory barriers that limit new entrants.
Summary
ELV stands out for trading at just 14.1x next year's earnings while consensus expects 14.3% EPS growth.
Where It Stands
The stock is up 20.13% over the past year, sits at a neutral RSI of 59.1, and trades at a 14.1x forward P/E — a discount to the healthcare sector median of 22x.
Key Metrics
- RSI: 59.1 — Neutral
- Trailing P/E: 16.1x
- Forward P/E: 14.1x
- PEG Ratio: 1.13
- Earnings Growth: +0.1%
- Revenue Growth: +0.1%
- Market Cap: $91.0B
- Dividend Yield: 0.02%
- 1-Year Return: 20.13%
- 52-Week High: $427.19
- 52-Week Low: $273.71
Analyst Consensus
18 Buy · 11 Hold · 0 Sell (29 analysts)
Bull Case
You're paying 14.1x forward earnings for 14.3% expected EPS growth, which is cheap for a national insurer with regulatory and scale advantages.
Bear Case
If the P/E reverts from 16.1x trailing to 12x (the low end for insurers), the stock could lose over 14% even if earnings meet expectations.
Catalyst to Watch
Watch for upcoming regulatory changes or large contract wins/losses, as either could materially shift forward earnings estimates.